The Mold & MCS page explains the proposed CIRS and biotoxin pathway by which mold exposure may drive chemical sensitivity — and the important caveat that CIRS, while well-developed in environmental medicine, is not yet established or widely accepted in mainstream medicine. This page covers what to actually do about a known or suspected mold problem — how to test your environment, what the results mean, how to find competent remediation, and how to know when a building cannot be made safe.
If you suspect mold is making you sick, the fastest useful answer is not a lab test — it is your own body. Do your symptoms measurably improve after several days away from a specific building, and come back when you return? That building-response pattern is the strongest early signal there is, it costs nothing, and it is something you can start documenting today.
Beyond that, testing matters enormously but only if it is the right test. The spore-trap air sampling used in most conventional mold inspections can come back clean in a building that is genuinely making you ill, because it does not capture what settles in dust. Knowing which test to ask for — and which results actually mean something — is what keeps you from spending money on an inspection that tells you nothing.
This page covers how to test, how to read the results, how to hire a remediator who will not make things worse, and the hardest question of all: how to know when a building cannot be made safe for you and it is time to leave.
Not all MCS is mold-driven.
But a meaningful subset of people with MCS may have underlying mold/biotoxin illness (described in the CIRS framework) from past or ongoing exposure, and distinguishing this subgroup matters because the approach is different and the building environment can be a direct obstacle to recovery.
The clinical indicators that mold and biotoxin burden may be a primary driver include: onset or significant worsening of symptoms following a move, water event, or time spent in a specific building; symptoms that improve when away from a particular building and return when you re-enter it; a constellation of symptoms that matches the CIRS presentation (fatigue, cognitive fog, unusual thirst, ice pick pain, static shocks, temperature dysregulation, alongside chemical sensitivity); and HLA-DR genotyping showing a susceptibility haplotype for biotoxin illness.
The most practical first indicator is the building response: do your symptoms improve measurably when you spend several days away from your primary residence or workplace, and return when you go back? This is not diagnostic — many things can cause this pattern — but a clear building-specific response is a strong signal that the building environment is a direct contributor to your symptom load rather than a background factor. Keep a symptom diary across several away-from-building and in-building periods to establish whether the pattern is consistent.
Before any testing, do a thorough visual inspection of the spaces you spend the most time in. Mold growth is frequently visible in the places where moisture accumulates: under sinks, around window frames, behind and under appliances, in basement corners, on bathroom caulking and grout, and on ceiling tiles or drywall below plumbing runs or roof penetrations. Visible mold growth is sufficient to warrant remediation regardless of testing. Testing is most valuable when the presence of mold is suspected but not visible — hidden mold inside walls, under flooring, or in HVAC systems.
A persistent musty or earthy odor — particularly one that is stronger in certain rooms or after the HVAC runs — indicates microbial volatile organic compound (MVOC) production from mold growth somewhere in the building. MVOCs are themselves biologically active compounds that can trigger reactions in sensitized individuals independent of the mycotoxin load. The smell does not confirm CIRS-relevant mold species — that requires testing — but it confirms active mold growth that warrants investigation. People with MCS often notice MVOC odors before they are detectable by others, which is a useful early warning capacity.
Mold testing varies enormously in what it measures and how useful it is for people with MCS and CIRS. The tests used in standard home inspections are often not the ones that provide clinically relevant information.
ERMI is a DNA-based dust test developed by the US EPA that measures the relative abundance of 36 mold species in settled dust collected from a single location (typically the main living area). It uses quantitative PCR to identify and quantify specific mold DNA, providing a numerical score that compares a home to a reference database of US homes. ERMI is the most clinically relevant test for CIRS purposes because it identifies the specific species that Shoemaker Protocol research has linked to biotoxin illness. Available through Mycometrics and other laboratories; collection requires a Swiffer cloth sample sent by mail.
HERTSMI-2 (Health Effects Roster of Type-Specific Formers of Mycotoxins and Inflammagens, 2nd version) is a subset of the ERMI that scores five of the most CIRS-relevant mold species: Stachybotrys chartarum, Aspergillus penicillioides, Aspergillus versicolor, Chaetomium globosum, and Wallemia seabis. It is less expensive than a full ERMI and more targeted for CIRS assessment. A HERTSMI-2 score above 11 is generally considered unsafe for CIRS-susceptible individuals. It is calculated from the same DNA analysis as ERMI and can often be derived from an ERMI test without additional sampling.
Standard air sampling using spore trap cassettes captures airborne mold spores and counts them by genus under a microscope. This is the test used in most conventional mold inspections. Its limitation for CIRS purposes is significant: spore trap testing identifies total spore counts and broad genera, but cannot distinguish between species, does not capture non-sporulating mold fragments, and does not measure mycotoxin load. A negative or low spore trap result does not rule out a CIRS-relevant mold problem. It is most useful for identifying gross contamination and comparing indoor to outdoor counts.
Shoemaker Protocol research has specifically validated the ERMI/HERTSMI-2 as the appropriate environmental standard for determining whether a building is safe for CIRS patients. Air sampling has not been validated for this purpose. A building can have normal spore trap results and a high ERMI score because ERMI measures DNA from settled dust — including non-sporulating fragments and dead mold — that air sampling does not capture. For CIRS purposes, use ERMI. Air sampling is a secondary tool for identifying active sporulating growth and confirming the effectiveness of remediation on airborne counts.
Tape lift samples taken from visible mold growth identify the species present on specific surfaces and can confirm whether growth is active. They are useful for directing remediation — knowing what species you are dealing with helps plan containment and treatment protocols — but they do not measure the overall building burden. A positive tape lift from visible growth confirms what visual inspection already indicates. Tape lift sampling is most useful post-remediation, to verify that treated areas have been successfully addressed.
HVAC systems can harbor significant mold growth within ductwork, on coils, and in air handling units, distributing mold fragments and mycotoxins throughout a building whenever the system runs. HVAC inspection and sampling by a qualified inspector is an essential component of any comprehensive mold assessment. Request direct inspection of the air handling unit, coils, and accessible ductwork in addition to dust sampling. A clean living area ERMI can coexist with significant HVAC mold burden if the ductwork has not been inspected.
Mold test results require context to interpret usefully. The same numerical value can mean different things depending on the test type, the patient’s HLA-DR status, and the specific species identified.
ERMI scores range from approximately −10 to +20. The reference population median is 0. For the general population, an ERMI above 2 is considered elevated. For CIRS-susceptible individuals (HLA-DR positive), Shoemaker Protocol research uses stricter thresholds: an ERMI score above 2 warrants attention, and scores above 5 are generally considered problematic for susceptible individuals. Some CIRS practitioners use a threshold of ERMI < 2 and HERTSMI-2 < 11 as the standard for a building being safe for CIRS treatment to proceed.
HERTSMI-2 scores are calculated from the five species counts using a weighted formula. A score of 10 or below is generally considered acceptable for CIRS-susceptible individuals. A score of 11–15 is in a caution range where remediation may be warranted depending on clinical context. A score above 15 is considered unsafe for CIRS-susceptible individuals and active remediation is indicated. These thresholds are clinical reference points from Shoemaker Protocol research, not regulatory standards.
Not all mold species carry equal CIRS risk. Stachybotrys chartarum (black mold) produces trichothecene mycotoxins and is among the most concerning. Aspergillus and Penicillium species produce aflatoxins, ochratoxin A, and other mycotoxins relevant to biotoxin illness. Chaetomium globosum produces chaetoglobosin, associated with neurological symptoms. Elevated counts of these species in an ERMI carry more clinical significance than equivalent elevations in species not associated with mycotoxin production. Your CIRS practitioner can help interpret which species findings are most relevant to your clinical picture.
A low ERMI score or negative air sampling does not rule out a mold problem if symptoms clearly track to the building. Mold can be sequestered in areas not captured by the sampling location, present in concentrations that affect susceptible individuals without being detectable at the sampled site, or present in a previous building that has since been vacated but whose biotoxin burden remains in the patient’s body. Negative results are reassuring but not conclusive when clinical indicators point strongly to a building-specific response. Consider additional sampling in different locations, HVAC inspection, or consultation with an indoor environmental professional (IEP) with CIRS experience.
The mold remediation industry is loosely regulated. There is significant variation in competence, protocol adherence, and understanding of what “complete” remediation means for chemically sensitive individuals. Screening remediators before hiring matters.
The most relevant certifications in mold remediation are from the Institute of Inspection, Cleaning and Restoration Certification (IICRC — S520 standard for mold remediation) and the American Council for Accredited Certification (ACAC — certifies Council-certified Microbial Remediators and Consultants). These certifications do not guarantee CIRS-specific competence, but they indicate training in standard remediation protocols. For CIRS-relevant remediation, ask specifically whether the remediator is familiar with Shoemaker Protocol standards and ERMI/HERTSMI-2 clearance testing.
The entity that tests your building should not be the same entity that remediates it. This is a fundamental conflict of interest: a remediator who also does the post-remediation clearance testing has financial motivation to pass their own work. Use an independent inspector — ideally a Certified Indoor Environmental Professional (CIEP) or Industrial Hygienist — for both pre-remediation assessment and post-remediation clearance testing. The remediator does the work; an independent party verifies it.
Walk away from any remediator who: quotes a price without inspecting the property; offers to “spray and fog” for mold without physical removal of contaminated materials; promises to eliminate all mold (mold is everywhere; the goal is to eliminate problematic growth, not all mold); does not provide a written scope of work before beginning; suggests that painting over mold growth is an acceptable treatment; or declines to provide references from previous clients. Antimicrobial fogging as a standalone treatment without physical removal is not remediation — it is temporary suppression that does not address the underlying contamination.
A competent remediator will: inspect the property thoroughly before quoting; provide a written scope of work identifying specific areas and materials to be addressed; explain their containment protocol (negative air pressure, physical barriers to prevent cross-contamination); specify how contaminated materials will be removed and disposed of; describe their post-remediation cleaning protocol; and welcome independent clearance testing by a third party. They should be able to discuss ERMI and HERTSMI-2 without needing an explanation of what those tests are.
Proper mold remediation is a physical removal process, not a chemical treatment process. Understanding what it actually involves helps you evaluate whether what you are being offered meets the standard.
The IICRC S520 standard — the industry reference for mold remediation — specifies that remediation involves physical removal of contaminated materials, not just treatment of surfaces. Drywall, insulation, carpet, and other porous materials that have been colonized by mold cannot be cleaned in place — they must be removed and replaced. Non-porous materials (concrete, glass, metal) can be cleaned with HEPA vacuuming and antimicrobial treatment, but the physical removal of contaminated porous materials is non-negotiable for effective remediation.
Before any physical work begins, the remediation area must be isolated from the rest of the building using physical barriers (polyethylene sheeting sealed to surfaces) and negative air pressure (HEPA air scrubbers exhausting air to the outside, keeping the remediation zone at lower pressure than adjacent areas so airborne mold fragments cannot migrate). Containment is not optional — without it, the remediation process itself distributes mold fragments throughout the building. Ask to see the containment setup before work begins.
Contaminated porous materials are removed, bagged in heavy plastic, and disposed of. The scope of removal should extend beyond visibly affected areas into adjacent materials, because mold growth typically extends further than the visible surface contamination. The standard is to remove to clean material — meaning the removal extends until unaffected material is reached on all sides of the contaminated zone. “Cut and run” approaches that remove only the visibly affected section without adequate margin typically result in regrowth.
After physical removal, all surfaces in the remediation area are HEPA vacuumed to capture settled mold fragments, then wiped with an antimicrobial solution. HEPA vacuuming is essential — standard vacuums with paper bags recirculate fine mold fragments back into the air. The cleaning sequence (HEPA vacuum first, wet wipe second) matters: reversing it stirs up particles that the vacuum should have captured first.
If the HVAC system has been involved — and it should be inspected regardless — contaminated duct sections, coil surfaces, and drain pans require treatment or replacement. Duct cleaning for mold is legitimate only when contamination has been confirmed; routine duct cleaning without confirmed contamination is not necessary and can disturb settled dust throughout the system. Coil cleaning is typically done with biocide treatment and physical cleaning. Severely contaminated sections of flexible ductwork are generally replaced rather than cleaned.
Tempted to run a hydroxyl or oxidant air device (like WellisAir) instead of, or during, remediation? See our honest look at air-cleaning devices and MCS — inactivating mold is not the same as removing it.
For most people with MCS and CIRS, the answer is no.
The remediation process itself is a significant exposure event, and the period during which containment is established and demolition is occurring is among the highest-exposure moments in the entire remediation process.
Even with proper containment and negative air pressure, physical disturbance of contaminated materials releases mold fragments and mycotoxins into the air of the remediation zone. Containment is designed to prevent this from migrating to the rest of the building, but containment is not perfect, particularly when workers are moving in and out of the containment area, when the building has shared HVAC, or when the contamination is extensive. For a chemically sensitive individual with CIRS, exposure during active remediation can set back recovery significantly.
If the remediation involves significant demolition (drywall removal, flooring removal, opening walls or ceilings), leave the building for the duration of the active work and for at least 24–48 hours afterward to allow settled dust to be captured by air filtration before re-entry. If the remediation involves HVAC system work, leave when the system is being disturbed and do not re-enter until the system has been run through several cycles with fresh filtration in place. Arrange alternative accommodation in advance rather than waiting to assess on the day — the decision to leave is easier when it is already planned.
Before re-entry after remediation, run portable air purifiers in the remediated areas for at least 24 hours. Request that the remediator provide air quality clearance (HEPA-vacuumed and wiped surfaces, no visible dust or debris) before your return. On first re-entry, assess cautiously: spend a short period in the space, pay attention to symptoms, and retreat if early warning signs appear. A full return should follow only after you have demonstrated that the space is tolerable over several visits. This staged re-entry is more conservative than what most remediators will tell you is necessary — it is appropriate for CIRS-susceptible individuals specifically.
Porous items (clothing, soft furnishings, mattresses, books, cardboard) that have been in a high-mold-burden building may carry mycotoxin contamination and can re-contaminate a remediated environment. For individuals with severe CIRS, contaminated soft goods are a genuine obstacle to recovery. Hard non-porous items can typically be wiped clean. The question of whether to replace porous items is one of the most practically difficult aspects of mold remediation for CIRS patients, and it should be discussed with your CIRS practitioner — the answer depends on the severity of your biotoxin burden and the extent of contamination.
Visual inspection and remediator sign-off are not sufficient clearance criteria for CIRS-susceptible individuals. Independent post-remediation testing against ERMI/HERTSMI-2 standards is the appropriate verification.
The remediator’s own assessment that work is complete is a starting point, not a conclusion. Independent clearance testing by the same indoor environmental professional who conducted the pre-remediation assessment provides an objective comparison between pre- and post-remediation conditions. For CIRS purposes, the clearance standard is an ERMI score below 2 and a HERTSMI-2 score of 10 or below — not just visual absence of mold growth.
Allow at least 24–48 hours after remediation completion before clearance testing. This allows settled dust from the remediation process to clear from the air. Testing too soon after completion can capture elevated counts from the remediation disturbance itself rather than the baseline post-remediation condition. If the HVAC system has been running since remediation completion, this helps distribute and filter residual fragments before testing.
A post-remediation ERMI or HERTSMI-2 that does not meet clearance standards indicates either that the remediation was incomplete, that there are additional mold sources not addressed in the original scope, or (in some cases) that the contamination level was so high that a single remediation cycle was insufficient. Return to the remediator with the clearance results and require re-work under the original contract before final payment. A reputable remediator will include a clearance standard in their contract; if yours did not, this is a lesson for future engagements.
The ultimate clearance test for a CIRS patient is clinical: do you feel meaningfully better after sustained time in the remediated space, and do your CIRS biomarkers move in the right direction during treatment? Environmental clearance testing verifies the building meets the objective standard. Clinical response confirms it is working for you specifically. Some individuals with severe HLA-DR susceptibility require HERTSMI-2 scores significantly below the 11 threshold to experience clinical improvement — their system is responsive to lower contamination levels than the population average. Work with your CIRS practitioner to establish your personal clearance threshold.
Remediation is not always feasible, affordable, or sufficient. Recognizing when a building cannot be made safe — and when continued occupancy is actively preventing recovery — is one of the most practically difficult decisions in CIRS management.
Some buildings cannot be adequately remediated. This is true when: the mold contamination is structural and pervasive (the building envelope itself has been compromised by chronic moisture intrusion); the landlord or building owner will not authorize or fund adequate remediation; the cost of remediation significantly exceeds the value of the property; or multiple remediation attempts have failed to bring ERMI/HERTSMI-2 below acceptable thresholds. In these situations, continued occupancy is not a waiting period — it is active ongoing exposure that maintains biotoxin burden and prevents any treatment from gaining traction.
The Shoemaker Protocol is explicit on this point: treatment cannot proceed while a patient remains in a CIRS-relevant mold environment. Binder therapy, VIP protocols, and other interventions are ineffective or actively counterproductive when ongoing exposure continues to replenish biotoxin burden faster than treatment can reduce it. If you are not responding to treatment and you remain in a building with an elevated ERMI or HERTSMI-2, the building is the obstacle. This is not a comfortable conclusion when relocation is financially or logistically difficult. It is, however, a clinical reality that the research supports clearly.
In most US jurisdictions, landlords have a legal obligation to maintain habitable conditions, and significant mold contamination affecting health is a habitability issue. Tenants who can document mold-related health impacts and the landlord’s failure to address them have legal remedies including rent withholding, repair-and-deduct, and lease termination without penalty in many states. The Disability Rights page covers the Fair Housing Act framework, which also applies to mold-related accommodation requests in rental housing. Document everything in writing before taking any action.
When evaluating new housing after a mold-related relocation, pre-move ERMI testing of the prospective property is the most reliable screen. Older buildings without a history of water events are not inherently safer than newer buildings — the relevant variable is moisture history, not age. Request disclosure of any past water damage, flooding, or mold remediation from the landlord or seller. Inspect all moisture-prone areas yourself. A brief trial period in the space — spending several hours there before committing — provides a clinical data point alongside the objective testing, and for CIRS-susceptible individuals, that clinical response is meaningful information.
CDC published five years of hospital surveillance in July 2026 showing that invasive mold disease — fungus growing into tissue — is undercounted and highly lethal in immunocompromised and critically ill patients. It is a serious finding, and it is being widely misreported as evidence about household mold. It is not: the study did not measure home exposure and did not determine where any patient encountered the mold. See our plain-language breakdown of what the CDC study does and does not show.
What is Multiple Chemical Sensitivity? MCS is a chronic, physiological condition causing reactions to everyday low-level…
Why is MCS so confusing? Different triggers, thresholds, and reactions per person; hills and valleys; and why "this cure…
The full by-system symptom list for Multiple Chemical Sensitivity: neurological, respiratory, fatigue, gastrointestinal,…
How does MCS work in the body? The five documented mechanisms: mast cell activation, TRPV1/TRPA1 receptor sensitization,…
Learn about TILT — Toxicant-Induced Loss of Tolerance — the two-stage mechanism behind Multiple Chemical Sensitivity…
What is electromagnetic hypersensitivity (EHS)? Symptoms, the documented overlap with MCS, peer-reviewed research on EMF…
How fibromyalgia and Multiple Chemical Sensitivity overlap: shared central sensitization, the documented comorbidity (55…
Work out what size air purifier you actually need: room volume, air changes per hour, required CADR in CFM, and the carb…
EDS is genetic — chemicals do not cause it. But EDS and Mast Cell Activation Syndrome (MCAS) frequently co-occur, and …
How ME/CFS (chronic fatigue syndrome) and MCS overlap: shared neuroinflammation, oxidative stress, and central sensitiza…
Free TILT Self-Assessment including the BREESI screener and QEESI — the gold standard for identifying chemical intoler…
Free printable MCS patient toolkit: doctor-visit packet, accommodation letters, symptom tracker, wallet card, one-page e…
How mold exposure triggers chemical sensitivity through CIRS and TILT. Biotoxin pathways, HLA genetics, testing, remedia…
The deep science behind CIRS: why certain HLA-DR gene types cannot clear mold biotoxins, the recirculation loop, HLA hap…
CDC surveillance found 449 invasive mold disease cases and 45% 90-day all-cause mortality. What the study actually shows…
The current state of MCS research: what the 2023 Molot review changed, TRP receptor modulation, biotoxin elimination adv…
Is Multiple Chemical Sensitivity psychological or physical? A plain-language comparison of the 2024 Brain Sciences psych…
The documented history of Multiple Chemical Sensitivity: from Theron Randolph's 1950s clinical observations through the …
77 peer-reviewed studies on chemical exposure, MCS, indoor air quality, and human health. Organised by category with ful…
Can you recover from MCS? Many people have. Testing, treatment pathways, and actionable steps for CIRS treatment, mast c…
The priority-ordered tests that identify what is driving your MCS: HLA-DR genotyping, CIRS biomarkers, mast cell markers…
A practical guide to navigating the medical system with MCS. Why most doctors get it wrong, which practitioners to seek,…
Evidence-based strategies for managing MCS toxic loads. Detoxification support, vagus nerve techniques, air filtration, …
Why people with MCS often react to food as well as chemicals. Histamine intolerance, mast cell activation, DAO enzyme de…
Comprehensive guide to MCS triggers — chemicals, foods, drugs — with practical alternatives and the Personal Precaut…
Indoor air can be 5x more polluted than outdoor air. Assessment tools, filtration guidance, safe building materials, and…
Can ozone remove new-couch or new-carpet VOC smell? No — it makes new pollutants. The safe fix: ventilation, bake-out,…
An honest, MCS-focused look at WellisAir and hydroxyl air-cleaning devices — what they do, what they don't, and whethe…
The canonical MCS air filter guide: why activated carbon is essential, which purification technologies to avoid, a 7-poi…
An honest, MCS-calibrated guide to fragrance-free cleaners and laundry detergent: why "unscented" is not the same as "fr…
Shampoo, moisturizer, deodorant, and sunscreen for MCS: vetted fragrance-free brands, why deodorant is the hardest categ…
The honest MCS guide to zero-VOC paint: what GREENGUARD Gold actually means (and doesn't), vetted MCS-specialty brands, …
Personal air protection for MCS away from home: a respirator with multi-gas P100 cartridges, a carbon disposable mask, a…
What makes a mattress safe or unsafe for people with MCS? GREENGUARD Gold explained, latex risk, mold prevention, and an…
MCS disability protections under the ADA, Fair Housing Act, Social Security, and international law. Workplace accommodat…
How to navigate public spaces, workplaces, travel, hotels, and everyday errands with MCS. Preparation strategies, legal …
The emotional consequences of MCS are real, documented, and devastating. Grief, identity loss, isolation, financial terr…
Does MCS run in families? How to identify chemical sensitivity in children, navigate school accommodations, protect chil…
How military toxic exposures connect to MCS. VA disability claims, the PACT Act, medical evidence, and support resources…
Real accounts of developing MCS, navigating diagnosis, reorganizing a life, and finding a way forward. Three documented …
A guide for partners, family, and friends of people with MCS. What is happening in their body, how to make visits safe, …
Plain-English definitions of 50+ medical and scientific terms used in MCS and CIRS. TILT, HLA-DR, MCAS, biotoxins, QEESI…
Answers to the most common questions about Multiple Chemical Sensitivity — diagnosis, treatment options, disability ri…